Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation

Graham McIlroyDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Emmanouil NikolousisDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Nervana Abou-ZeidDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Paneesha ShankaraDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Bhuvan KishoreDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Maria KaparouDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Richard LovellDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Shereef ElmoamlyDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland; ;Internal Medicine and Clinical Hematology Department, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Egypt

David DaviesDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Claire HorganDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Amir ShenoudaDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland;

Alexandros KanellopoulosDepartment of Haematology, University Hospitals Birmingham, Birmingham, United Kingdom of Great Britain and Northern Ireland; Correspondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

No potential conflict of interest was reported by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation

Information for

Open access

Opportunities

Help and information

Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation

Disclosure statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature